Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1994-02-20
1995-06-27
Hollinden, Gary E.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514336, 514337, 514355, 514353, 514414, 514422, A61K 31505, A61K 3144, A61K 3140, A61K 3150
Patent
active
054280397
ABSTRACT:
While performing cardiopulmonary bypass, the aorta is cross-clamped and the beating heart is stopped by introducing of an ATP-dependent potassium channel opening agent. The infusion into the coronary circulation shortens the cardiac action potential thereby arresting the heart muscle at a hyperpolarized membrane potential. This maintains the heart in a state of minimal metabolic requirement, thereby preserving transmembrane ionic gradients, intercellular energy stores and cellular integrity. Cardiac arrest is reversed simply by flushing the heart by the coronary circulation upon removal of the aortic cross-clamp. This use is also germane to organ preservation during transport for transplantation. For example, the donor heart is arrested using an ATP-dependent potassium channel opening agent, it is then removed and transported to the recipient and transplanted. Cardiac arrest is reversed by reperfusing the orthotropic graft.
REFERENCES:
patent: 4908378 (1990-03-01), Soll et al.
patent: 5139789 (1992-08-01), Baumgarten
patent: 5256688 (1993-10-01), Grover et al.
patent: 5268374 (1993-12-01), Fung et al.
patent: 5278169 (1994-01-01), Atwal et al.
Richer, et al., "Cardiovascular and Biological Effects of K+ Channel Openers, A Class of Drugs with Vasorelaxant and Cardioprotective Properties," Life Sciences, 1990, 47 (19), pp. 1693-1705.
Cohen, et al., "Elective cardiac arrest with a hyperpolarizing adenosine triphosphate-sensitive potassium channel opener," The Journal of Thoracic and Cardiovascular Surgery, Aug. 1993, pp. 317-328.
Cohen, et al., "Hyperpolarized Elective Cardiac Arrest with an ATP-Sensitive Potassium Channel Opener," Pace, vol. 16, Apr. 1993, Part II, p. 79.
Tips, "K+ channel openers and `natural` cardioprotection," Jul. 1992, vol. 13, pp. 269-271.
Auchampach et al., "The New K.sup.+ Channel Opener Aprikalim (RP52891) Reduces Experimental . . . , " J. Pharmacol. Exp. Ther., 259(2), 961-967 (1991).
Arena et al., "Activation of ATP-sensitive K.sup.+ Channels in heart cells by pinacidil . . . , " Am. J. Physiol., 257(6, Pt. 2), H2092-H2096 (1989).
Minkes et al., "Analysis of pulmonary & systemic vascular responses to cromakalim,". . . Am. J. Physiol. 260 (3, Pt. 2) H957 H966 (1991).
Escande et al., "The potassium channel opener cromakalim (BRL34915) activates . . . ," Biochem. Biophys. Pres. Commun., 154(2) 620-5 (1988).
Sanguinetti et al., "BRL 34915 (cromakalim) activates ATP-sensitive K.sup.+ current in cardiac muscle," Proc. Natl. Acad. Sci USA, 85 (21), 8360-8364 (1988).
Ripoll et al., "Modulation of ATP-Sensitive K.sup.+ Channel Activity & Contractile Behavior in Mammalian . . . ," J. Pharmacol. Exp. Ther., 255(2), 429-435, (1990).
Satoh et al., "Cardioprotective Actions of ATP-Sensitive K.sup.+ Channel Openers (Cromakalim . . . ," J. Nara Med. Ass., 44, 37-46, (1993).
Cebulak Mary
Hollinden Gary E.
The Center for Innovative Technology
LandOfFree
Method for electively achieving reversible hyperpolarized cardia does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for electively achieving reversible hyperpolarized cardia, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for electively achieving reversible hyperpolarized cardia will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-287745